Success Metrics

Clinical Success Rate
77.8%

Based on 14 completed trials

Completion Rate
78%(14/18)
Active Trials
0(0%)
Results Posted
57%(8 trials)
Terminated
4(19%)

Phase Distribution

Ph phase_1
1
5%
Ph phase_3
7
33%
Ph not_applicable
1
5%
Ph phase_2
12
57%

Phase Distribution

1

Early Stage

12

Mid Stage

7

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
1(4.8%)
Phase 2Efficacy & side effects
12(57.1%)
Phase 3Large-scale testing
7(33.3%)
N/ANon-phased studies
1(4.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

73.7%

14 of 19 finished

Non-Completion Rate

26.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

21

all time

Status Distribution
Completed(14)
Terminated(5)
Other(2)

Detailed Status

Completed14
Terminated4
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
0
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (4.8%)
Phase 212 (57.1%)
Phase 37 (33.3%)
N/A1 (4.8%)

Trials by Status

terminated419%
withdrawn15%
completed1467%
unknown210%

Recent Activity

0 active trials
Showing 5 of 21
completedphase_3

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

NCT01261793
completedphase_2

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821
completedphase_3

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

NCT01408576
completedphase_3

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

NCT01262365
completedphase_2

Multi-centric Study

NCT01219816
View all 21 trials

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT01261793Phase 3

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Completed
NCT00301821Phase 2

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed
NCT01408576Phase 3

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

Completed
NCT01262365Phase 3

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Completed
NCT01219816Phase 2

Multi-centric Study

Completed
NCT00098839Phase 1

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed
NCT00945815Phase 2

S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
NCT00553501Phase 2

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Completed
NCT01534403Phase 2

Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

Completed
NCT00941928Phase 2

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated
NCT00382837Phase 3

Study of Epratuzumab in Systemic Lupus Erythematosus

Withdrawn
NCT00042913Phase 2

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

Unknown
NCT00022685Phase 3

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

Unknown
NCT00383513Phase 2

Study of Epratuzumab in Systemic Lupus Erythematosus

Completed
NCT00660881Phase 2

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Completed
NCT00383214Phase 3

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Terminated
NCT00113971Phase 2

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Terminated
NCT00111306Phase 3

Study of Epratuzumab in Systemic Lupus Erythematosus

Terminated
NCT00624351Phase 2

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Completed
NCT00398372Not Applicable

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21